FocalTherics reported a 39% increase in high-intensity focused ultrasound (HIFU) revenue during its second-quarter earnings call on Tuesday [1].
The growth indicates a rapid adoption of the company's medical technology platform. This momentum arrives as the firm completes a significant capital raise to fund further operations.
Management said system sales jumped 44% [1]. These figures suggest a strong market reception for the HIFU platform. During the call, the company's chief financial officer reaffirmed the 2026 HIFU revenue outlook of $50 million to $54 million [2].
Beyond the quarterly earnings, FocalTherics announced the closing of a $40 million equity offering [2]. This injection of capital provides a liquidity cushion as the company scales its commercial efforts.
The financial results follow a broader corporate transition. A company spokesperson said the current period is a transformative moment in the company's history, which includes the transition of its name from EDAP to FocalTherics [3].
Louisa Smith of Gilmartin Group represented management during the recorded conference call. The company used the session to highlight adoption momentum and provide updated guidance to investors [1, 2].
“HIFU revenue surged 39% as system sales jumped 44%, signaling strong adoption momentum.”
The simultaneous rise in system sales and the successful closing of a $40 million equity offering suggest that FocalTherics is successfully transitioning from a rebranding phase into a growth phase. By maintaining its revenue guidance despite the volatility of medical device adoption, the company is signaling to investors that its HIFU technology has reached a sustainable market trajectory.
